Evidence map›Paper›PMID 23536279›Full record

ArticlePathology oncology research : POR2013

High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Jana Smardova, Kvetoslava Liskova, Barbora Ravcukova, Lenka Kubiczkova, Sabina Sevcikova, Jaroslav Michalek, Miluse Svitakova, Vaclav Vybihal, Leos Kren, Jan Smarda

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jana SmardovaDepartment of Pathology, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic. janasmarda@seznam.cz
Kvetoslava Liskova
Barbora Ravcukova
Lenka Kubiczkova
Sabina Sevcikova
Jaroslav Michalek
Miluse Svitakova
Vaclav Vybihal
Leos Kren
Jan Smarda
University Hospital Brno · CZMasaryk University · CZLaboratory of Molecular Genetics · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most common and the most aggressive type of brain cancer. Aberrations of the RTK/RAS/PI3K-, p53-, and RB cell signaling pathways were recognized as a core requirement for pathogenesis of glioblastoma. The p53 tumor suppressor functions as a transcription factor transactivating expression of its target genes in response to various stress stimuli. We determined the p53 status in 36 samples of glioblastoma by functional analyses FASAY and split assay. Seventeen p53 mutations were detected and further analyzed by cDNA and gDNA sequencing in 17 patients (47.2 %). Fifteen (88.2 %) of the mutations were missense mutations causing amino acid substitutions, seven of them exhibited temperature-sensitivity. Two mutations were determined as short deletions, one of them causing formation of premature termination codon in position 247. Fluorescent in situ hybridization revealed the loss of the p53-specific 17p13.3 locus in four of 33 analyzed samples (12 %). In 12 out of 30 samples (40 %), the p53 protein accumulation was shown by immunoblotting. There was high (80 %) concordance between the presence of the clonal p53 mutation and the p53 protein accumulation.

Indexed as

Genes, p53MutationAgedBrain NeoplasmsCell Line, TumorDNA Mutational AnalysisFemaleGene DeletionGlioblastomaHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedOrgan SpecificitySequence Analysis, DNATemperatureTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID23536279
OpenAlexW1963824881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.